Kestrel

Specialised Diagnostic testing for early invasive breast cancer patients

Somerset NHS Foundation Trust · published Thu 19 Mar 2026

In plain English

Reading the notice and writing a summary. This takes a few seconds the first time.

The notice doesn't say where the documents are, but Somerset NHS Foundation Trust's other tenders use Atamis. Register there (it's free) and look for this tender, or email the buyer's contact on the notice.

The notice as published

Provision of the Oncotype DX Breast Recurrence Score test. Oncotype DX genomic testing for breast cancer.<br/><br/>This notice is confirmation of an award having been made based on a framework agreement and without competition.<br/><br/>The lifetime value of the contract is expected to be £326,700.00 call off order.<br/><br/>The contract dates are 14 March 2026 to 13 March 2027. <br/><br/>This is an existing service with an existing provider.